(E)-3-[4-[[2-(furan-2-ylsulfonyl-(2-methylpropyl)amino)-5-(trifluoromethyl)phenoxy]methyl]phenyl]prop-2-enoic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-3-[4-[[2-(furan-2-ylsulfonyl-(2-methylpropyl)amino)-5-(trifluoromethyl)phenoxy]methyl]phenyl]prop-2-enoic acid
• 英文别名: (E)-3-[4-[[2-[furan-2-ylsulfonyl(2-methylpropyl)amino]-5-(trifluoromethyl)phenoxy]methyl]phenyl]prop-2-enoic acid
• 化学式: C₂₅H₂₄F₃NO₆S
• 分子量: 523.5
• InChiKey: LOQMSUDLLHPPHQ-FMIVXFBMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  36
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  105
• 氢给体数：
  1
• 氢受体数：
  10

文献信息

• Remedies for depression containing ep1 antagonist as the active ingredient
  申请人：——

  公开号：US20040082653A1

  公开（公告）日：2004-04-29

  A pharmaceutical composition for the treatment and/or prevention of depression comprising a compound having an antagonistic activity for EP 1 receptor which a prostaglandin E 2 receptor subtype. EP 1 antagonist is useful for the treatment of depression, for example, endogenous depression, reactive depression, weatherability depression, neurological depressed state, the depressed state of brain organic mental disorder.

  一种用于治疗和/或预防抑郁症的药物组合物，包括一种具有EP1受体拮抗活性的化合物，该受体是前列腺素E2受体亚型。EP1拮抗剂对于治疗抑郁症很有用，例如内源性抑郁症，反应性抑郁症，耐受性抑郁症，神经学抑郁状态，脑器质性心境障碍的抑郁状态。
• Sulfonamide and carboxamide derivatives and drugs containing the same as the active ingredient
  申请人：——

  公开号：US20030060460A1

  公开（公告）日：2003-03-27

  The sulfonamide or carboamide derivatives of the formula (I) and a pharmaceutical composition which comprise them as an active ingredient: 1 (wherein A ring, B ring is carbocyclic ring, heterocyclic ring; Z 1 is —COR 1 , —CH═CH—COR 1 etc.; Z 2 is H, alkyl etc.; Z 3 is single bond, alkylene; Z 4 is SO 2 , CO; Z 5 is alkyl, phenyl, heterocyclic ring etc.; R 2 is CONR 8 , O, S, NZ 6 , Z 7 -alkylene, alkylene etc.; R 3 is H, alkyl, halogen, CF 3 etc.; R 4 is H, (substituted) alkyl etc.; n, t is 1-4). The compounds of the formula (I) can bind to receptors of PGE 2 and show antagonistic activity against the action thereof or agonistic activity. Therefore, they are considered to be useful as medicine for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, medicine for increase of vesical capacity or medicine for uterine contraction, cathartic, suppression of gastric acid secretion, antihypertensive or diuretic agents.

  公式（I）的磺酰胺或羧酰胺衍生物以及包含它们作为活性成分的制药组合物： 1（其中A环，B环为碳环，杂环；Z1为—COR1，—CH═CH—COR1等；Z2为H，烷基等；Z3为单键，烷基；Z4为SO2，CO；Z5为烷基，苯基，杂环等；R2为CONR8，O，S，NZ6，Z7-烷基，烷基等；R3为H，烷基，卤素，CF3等；R4为H，（取代）烷基等；n，t为1-4）。 公式（I）的化合物可以与PGE2受体结合，并显示其作用的拮抗活性或激动活性。因此，它们被认为是用于抑制子宫收缩、镇痛药、止泻药、催眠剂、增加膀胱容量的药物或子宫收缩药物、泻药、抑制胃酸分泌、降压或利尿剂的有用药物。
• N-PHENYLARYLSULFONAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND AS ACTIVE INGREDIENT, SYNTHETIC INTERMEDIATE FOR THE COMPOUND AND PROCESS FOR IT'S PREPARATION
  申请人：NAGANAWA Atsushi

  公开号：US20100041708A1

  公开（公告）日：2010-02-18

  An N-phenylarylsulfonylamide compound of formula (I) (R 1 is COOH etc.; R 2 is hydrogen, methyl, etc.; R 3 and R 4 are a combination of methyl and methyl, etc.; R 5 is isopropyl etc.; Ar is thiazolyl, pyridyl, 5-methyl-2-furyl each optionally substituted with methyl; n is zero or 1), a synthetic intermediate for the compound and a process for its preparation. The compound of formula (I) binds to a prostaglandin E 2 receptor, especially an EP 1 subtype receptor, and antagonizes it. It is less affected by protein binding, so it has a satisfactory in vivo activity. Therefore, it is considered to be useful as an analgesic, an antipyretic agent, an agent for the treatment of pollakiuria (frequent urination) and/or lower urinary tract disease syndrome or an antineoplastic agent.

  化合物(I)是一种N-苯基磺酰胺化合物，其化学式为（R1为COOH等；R2为氢，甲基等；R3和R4为甲基和甲基的组合等；R5为异丙基等；Ar为噻唑基，吡啶基，5-甲基-2-呋喃基，每个基团可选地被甲基取代；n为零或1），用于该化合物的合成中间体和其制备方法。化合物(I)与前列腺素E2受体结合，特别是EP1亚型受体，并拮抗其作用。它受蛋白结合的影响较小，因此具有令人满意的体内活性。因此，它被认为是一种有用的镇痛剂，退烧剂，用于治疗多尿和/或下尿路疾病综合症或抗肿瘤剂的药剂。
• Method for the Prevention and/or Treatment of Neurodegenerative Diseases Characterized by Administering and Ep1 Receptor Antagonist
  申请人：Dore Sylvain

  公开号：US20080312326A1

  公开（公告）日：2008-12-18

  The present invention relates to the use of EP 1 receptor antagonists for the treatment of neurodegenerative diseases, for example, Alzheimer's disease, Parkinson's disease, Parkinson syndrome, dementia, amyotrophic lateral sclerosis, progressive supranuclear palsy, Huntington's disease, spinocerebellar ataxia, etc.

  本发明涉及使用EP1受体拮抗剂治疗神经退行性疾病，例如阿尔茨海默病、帕金森病、帕金森综合症、痴呆、肌萎缩性侧索硬化症、进行性核上性麻痹、亨廷顿病、脊髓小脑性共济失调等。
• SULFONAMIDE AND CARBOXAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP0947500A1

  公开（公告）日：1999-10-06

  The sulfonamide or carboamide derivatives of the formula (I) and a pharmaceutical composition which comprise them as an active ingredient: (wherein A ring, B ring is carbocyclic ring, heterocyclic ring; Z1 is -COR1, -CH=CH-COR1 etc.; Z2 is H, alkyl etc.; Z3 is single bond, alkylene; Z4 is SO2, CO; Z5 is alkyl, phenyl, heterocyclic ring etc.; R2 is CONR8, O, S, NZ6, Z7-alkylene, alkylene etc.; R3 is H, alkyl, halogen, CF3 etc.; R4 is H, (substituted) alkyl etc.; n, t is 1-4). The compounds of the formula (I) can bind to receptors of PGE2 and show antagonistic activity against the action thereof or agonistic activity. Therefore, they are considered to be useful as medicine for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, medicine for increase of vesical capacity or medicine for uterine contraction, cathartic, suppression of gastric acid secretion, antihypertensive or diuretic agents.

  式(I)的磺酰胺或羧酰胺衍生物以及包含它们作为活性成分的药物组合物： (其中 A 环、B 环为碳环、杂环；Z1 为-COR1、-CH=CH-COR1 等；Z2 为 H、烷基等；Z3 为单键、亚烷基；Z4 为 SO2、CO；Z5 为烷基、苯基、杂环等。R2 是 CONR8、O、S、NZ6、Z7-烷基、亚烷基等；R3 是 H、烷基、卤素、CF3 等；R4 是 H、（取代的）烷基等；n、t 是 1-4）。 式（I）化合物可与 PGE2 受体结合，并显示出对其作用的拮抗活性或激动活性。因此，它们被认为可用作抑制子宫收缩的药物、镇痛药、止泻药、睡眠诱导剂、增加膀胱容量的药物或子宫收缩的药物、泻药、抑制胃酸分泌的药物、降压药或利尿剂。